Changes in Histidine Decarboxylase, Histamine N-Methyltransferase and Histamine Receptors in Neuropsychiatric Disorders

  • Ling Shan
  • Ai-Min Bao
  • Dick F. Swaab
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 241)


Compared to other monoamine neurotransmitters, information on the association between the histaminergic system and neuropsychiatric disorders is scarce, resulting in a lack of histamine-related treatment for these disorders. The current chapter tries to combine information obtained from genetic studies, neuroimaging, post-mortem human brain studies and cerebrospinal fluid measurements with data from recent clinical trials on histamine receptor agonists and antagonists, with a view to determining the possible role of the histaminergic system in neuropsychiatric disorders and to pave the way for novel histamine-related therapeutic strategies.


Histamine Histidine decarboxylase Histamine receptors Histamine N-methyltransferase Neurodegenerative diseases Mood disorders Intellectual disability 



Alzheimer’s disease


Cerebrospinal fluid


Histamine 1–4 receptors


l-Histidine decarboxylase


Histamine N-methyltransferase


Messenger RNA


Parkinson’s disease




Tuberomamillary nucleus



Original research supported by the China Scholarship Council for State Scholarship Fund [grant number (2007) 3020] to Dr. Ling Shan and the China programme of introducing talents of discipline to universities (B13026) to Prof Ai-min Bao and Prof Dick F. Swaab. The work has been awarded a Young Investigators Award by the European histamine research society to Dr. Ling Shan who currently supported by a 2014 NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation. The authors are also grateful to the Netherlands Brain Bank (Director Dr. Inge Huitinga) for providing human brain material and clinical details, and to Mrs. W.T.P. Verweij for secretarial assistance.

Conflicts of Interest: We declare that we have no conflicts of interest.


  1. Agundez JA, Luengo A, Herraez O, Martinez C, Alonso-Navarro H, Jimenez-Jimenez FJ, Garcia-Martin E (2008) Nonsynonymous polymorphisms of histamine-metabolising enzymes in patients with Parkinson’s disease. Neuromolecular Med 10:10–16CrossRefPubMedGoogle Scholar
  2. Anichtchik OV, Rinne JO, Kalimo H, Panula P (2000) An altered histaminergic innervation of the substantia nigra in Parkinson’s disease. Exp Neurol 163:20–30CrossRefPubMedGoogle Scholar
  3. Beermann S, Seifert R, Neumann D (2012) Commercially available antibodies against human and murine histamine H(4)-receptor lack specificity. Naunyn Schmiedebergs Arch Pharmacol 385:125–135CrossRefPubMedGoogle Scholar
  4. Brioni JD, Esbenshade TA, Garrison TR, Bitner SR, Cowart MD (2011) Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer’s disease. J Pharmacol Exp Ther 336:38–46CrossRefPubMedGoogle Scholar
  5. Canellas F, Lin L, Julia MR, Clemente A, Vives-Bauza C, Ollila HM, Hong SC, Arboleya SM, Einen MA, Faraco J, Fernandez-Vina M, Mignot E (2014) Dual cases of type 1 narcolepsy with schizophrenia and other psychotic disorders. J Clin Sleep Med 10:1011–1018PubMedCentralPubMedGoogle Scholar
  6. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301:386–389CrossRefPubMedGoogle Scholar
  7. Castellan Baldan L, Williams KA, Gallezot JD, Pogorelov V, Rapanelli M, Crowley M, Anderson GM, Loring E, Gorczyca R, Billingslea E, Wasylink S, Panza KE, Ercan-Sencicek AG, Krusong K, Leventhal BL, Ohtsu H, Bloch MH, Hughes ZA, Krystal JH, Mayes L, de Araujo I, Ding YS, State MW, Pittenger C (2014) Histidine decarboxylase deficiency causes tourette syndrome: parallel findings in humans and mice. Neuron 81:77–90CrossRefPubMedGoogle Scholar
  8. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98:437–451CrossRefPubMedGoogle Scholar
  9. Chen MH, Bai YM, Chen YS, Huang KL, Hsu JW, Su TP (2014) Comorbidity of narcolepsy and schizophrenia in an adolescent patient. J Chin Med Assoc 77:598–600CrossRefPubMedGoogle Scholar
  10. Connelly WM, Shenton FC, Lethbridge N, Leurs R, Waldvogel HJ, Faull RL, Lees G, Chazot PL (2009) The histamine H4 receptor is functionally expressed on neurons in the mammalian CNS. Br J Pharmacol 157:55–63PubMedCentralCrossRefPubMedGoogle Scholar
  11. Correa BB, Xavier M, Guimaraes J (2006) Association of Huntington’s disease and schizophrenia-like psychosis in a Huntington’s disease pedigree. Clin Pract Epidemiol Ment Health 2:1PubMedCentralCrossRefPubMedGoogle Scholar
  12. Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, Lehert P, Ding CL, Lecomte JM, Schwartz JC (2013) Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol 12:1068–1075CrossRefPubMedGoogle Scholar
  13. Douglass AB, Hays P, Pazderka F, Russell JM (1991) Florid refractory schizophrenias that turn out to be treatable variants of HLA-associated narcolepsy. J Nerv Ment Dis 179:12–17. discussion 18CrossRefPubMedGoogle Scholar
  14. Douglass AB, Shipley JE, Haines RF, Scholten RC, Dudley E, Tapp A (1993) Schizophrenia, narcolepsy, and HLA-DR15, DQ6. Biol Psychiatry 34:773–780CrossRefPubMedGoogle Scholar
  15. Egan M, Yaari R, Liu L, Ryan M, Peng Y, Lines C, Michelson D (2012) Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD. Curr Alzheimer Res 9:481–490CrossRefPubMedGoogle Scholar
  16. Egan MF, Zhao X, Gottwald R, Harper-Mozley L, Zhang Y, Snavely D, Lines C, Michelson D (2013) Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia. Schizophr Res 146:224–230CrossRefGoogle Scholar
  17. Ercan-Sencicek AG, Stillman AA, Ghosh AK, Bilguvar K, O’Roak BJ, Mason CE, Abbott T, Gupta A, King RA, Pauls DL, Tischfield JA, Heiman GA, Singer HS, Gilbert DL, Hoekstra PJ, Morgan TM, Loring E, Yasuno K, Fernandez T, Sanders S, Louvi A, Cho JH, Mane S, Colangelo CM, Biederer T, Lifton RP, Gunel M, State MW (2010) L-histidine decarboxylase and Tourette’s syndrome. N Engl J Med 362:1901–1908PubMedCentralCrossRefPubMedGoogle Scholar
  18. Feliszek M, Speckmann V, Schacht D, von Lehe M, Stark H, Schlicker E (2015) A search for functional histamine H4 receptors in the human, guinea pig and mouse brain. Naunyn Schmiedebergs Arch Pharmacol 388:11–17CrossRefPubMedGoogle Scholar
  19. Fernandez-Guasti A, Kruijver FP, Fodor M, Swaab DF (2000) Sex differences in the distribution of androgen receptors in the human hypothalamus. J Comp Neurol 425:422–435CrossRefPubMedGoogle Scholar
  20. Fortuyn HA, Lappenschaar GA, Nienhuis FJ, Furer JW, Hodiamont PP, Rijnders CA, Lammers GJ, Renier WO, Buitelaar JK, Overeem S (2009) Psychotic symptoms in narcolepsy: phenomenology and a comparison with schizophrenia. Gen Hosp Psychiatry 31:146–154CrossRefPubMedGoogle Scholar
  21. Galeotti N, Sanna MD, Ghelardini C (2013) Pleiotropic effect of histamine H4 receptor modulation in the central nervous system. Neuropharmacology 71:141–147CrossRefPubMedGoogle Scholar
  22. Galici R, Boggs JD, Aluisio L, Fraser IC, Bonaventure P, Lord B, Lovenberg TW (2009) JNJ-10181457, a selective non-imidazole histamine H(3) receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition. Neuropharmacology 56:1131–1137CrossRefPubMedGoogle Scholar
  23. Garbarg M, Javoy-Agid F, Schwartz JC, Agid Y (1983) Brain histidine decarboxylase activity in Parkinson’s disease. Lancet 1:74–75CrossRefPubMedGoogle Scholar
  24. Giannoni P, Medhurst AD, Passani MB, Giovannini MG, Ballini C, Corte LD, Blandina P (2010) Regional differential effects of the novel histamine H3 receptor antagonist 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-p yridinecarboxamide hydrochloride (GSK189254) on histamine release in the central nervous system of freely moving rats. J Pharmacol Exp Ther 332:164–172PubMedCentralCrossRefPubMedGoogle Scholar
  25. Grove RA, Harrington CM, Mahler A, Beresford I, Maruff P, Lowy MT, Nicholls AP, Boardley RL, Berges AC, Nathan PJ, Horrigan JP (2014) A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer’s disease. Curr Alzheimer Res 11:47–58CrossRefPubMedGoogle Scholar
  26. Haas H, Panula P (2003) The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev 4:121–130CrossRefGoogle Scholar
  27. Haas HL, Sergeeva OA, Selbach O (2008) Histamine in the nervous system. Physiol Rev 88:1183–1241CrossRefPubMedGoogle Scholar
  28. Haig GM, Bain E, Robieson W, Othman AA, Baker J, Lenz RA (2014) A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia. Schizophr Bull 40:1433–1442PubMedCentralCrossRefPubMedGoogle Scholar
  29. Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, Sugiyama F, Yagami K, Goto K, Yanagisawa M, Sakurai T (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30:345–354CrossRefPubMedGoogle Scholar
  30. Heidari A, Tongsook C, Najafipour R, Musante L, Vasli N, Garshasbi M, Hu H, Mittal K, McNaughton AJ, Sritharan K, Hudson M, Stehr H, Talebi S, Moradi M, Darvish H, Arshad Rafiq M, Mozhdehipanah H, Rashidinejad A, Samiei S, Ghadami M, Windpassinger C, Gillessen-Kaesbach G, Tzschach A, Ahmed I, Mikhailov A, Stavropoulos DJ, Carter MT, Keshavarz S, Ayub M, Najmabadi H, Liu X, Ropers HH, Macheroux P, Vincent JB (2015) Mutations in the histamine N-methyltransferase gene, HNMT, are associated with nonsyndromic autosomal recessive intellectual disability. Hum Mol Genet 24:5697–5710PubMedCentralCrossRefPubMedGoogle Scholar
  31. Higuchi M, Yanai K, Okamura N, Meguro K, Arai H, Itoh M, Iwata R, Ido T, Watanabe T, Sasaki H (2000) Histamine H(1) receptors in patients with Alzheimer’s disease assessed by positron emission tomography. Neuroscience 99:721–729CrossRefPubMedGoogle Scholar
  32. Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 334:345–348CrossRefPubMedGoogle Scholar
  33. Homberg JR, van den Hove DL (2012) The serotonin transporter gene and functional and pathological adaptation to environmental variation across the life span. Prog Neurobiol 99:117–127CrossRefPubMedGoogle Scholar
  34. Horton JR, Sawada K, Nishibori M, Zhang X, Cheng X (2001) Two polymorphic forms of human histamine methyltransferase: structural, thermal, and kinetic comparisons. Structure 9:837–849PubMedCentralCrossRefPubMedGoogle Scholar
  35. Howland RH (1997) Sleep-onset rapid eye movement periods in neuropsychiatric disorders: implications for the pathophysiology of psychosis. J Nerv Ment Dis 185:730–738CrossRefPubMedGoogle Scholar
  36. Inocente C, Arnulf I, Bastuji H, Thibault-Stoll A, Raoux A, Reimao R, Lin JS, Franco P (2012) Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol 35:55–60CrossRefPubMedGoogle Scholar
  37. Ito C, Morisset S, Krebs MO, Olie JP, Loo H, Poirier MF, Lannfelt L, Schwartz JC, Arrang JM (2000) Histamine H2 receptor gene variants: lack of association with schizophrenia. Mol Psychiatry 5:159–164CrossRefPubMedGoogle Scholar
  38. Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, Lieberman JA, Marder SR, Maruff P, McMahon RP, Seidman LJ, Peykamian MA (2015) A Phase II study of a histamine H(3) receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophr Res 164:136–142CrossRefPubMedGoogle Scholar
  39. Jimenez-Jimenez FJ, Alonso-Navarro H, Garcia-Martin E, Agundez JA (2016) Thr105Ile (rs11558538) polymorphism in the histamine N-methyltransferase (HNMT) gene and risk for Parkinson disease: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 95:e4147CrossRefGoogle Scholar
  40. John J, Thannickal TC, McGregor R, Ramanathan L, Ohtsu H, Nishino S, Sakai N, Yamanaka A, Stone C, Cornford M, Siegel JM (2013) Greatly increased numbers of histamine cells in human narcolepsy with cataplexy. Ann Neurol 74:786–793CrossRefPubMedGoogle Scholar
  41. Kaminsky R, Moriarty TM, Bodine J, Wolf DE, Davidson M (1990) Effect of famotidine on deficit symptoms of schizophrenia. Lancet 335:1351–1352CrossRefPubMedGoogle Scholar
  42. Kano M, Fukudo S, Tashiro A, Utsumi A, Tamura D, Itoh M, Iwata R, Tashiro M, Mochizuki H, Funaki Y, Kato M, Hongo M, Yanai K (2004) Decreased histamine H1 receptor binding in the brain of depressed patients. Eur J Neurosci 20:803–810CrossRefPubMedGoogle Scholar
  43. Karlstedt K, Jin C, Panula P (2013) Expression of histamine receptor genes Hrh3 and Hrh4 in rat brain endothelial cells. Br J Pharmacol 170:58–66PubMedCentralCrossRefPubMedGoogle Scholar
  44. Kennedy SH, Giacobbe P, Rizvi SJ, Placenza FM, Nishikawa Y, Mayberg HS, Lozano AM (2011) Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years. Am J Psychiatry 168:502–510CrossRefPubMedGoogle Scholar
  45. Kishi T, Iwata N (2015) Efficacy and tolerability of histamine-2 receptor antagonist adjunction of antipsychotic treatment in Schizophrenia: a meta-analysis of randomized placebo-controlled trials. Pharmacopsychiatry 48:30–36PubMedGoogle Scholar
  46. Krystal AD (2009) A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev 13:265–274CrossRefPubMedGoogle Scholar
  47. Krystal AD, Richelson E, Roth T (2013) Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications. Sleep Med Rev 17:263–272CrossRefPubMedGoogle Scholar
  48. Kubo M, Kishi T, Matsunaga S, Iwata N (2015) Histamine H3 receptor antagonists for Alzheimer’s disease: a systematic review and meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis 48:667–671CrossRefPubMedGoogle Scholar
  49. Ledesma MC, Garcia-Martin E, Alonso-Navarro H, Martinez C, Jimenez-Jimenez FJ, Benito-Leon J, Puertas I, Rubio L, Lopez-Alburquerque T, Agundez JA (2008) The nonsynonymous Thr105Ile polymorphism of the histamine N-methyltransferase is associated to the risk of developing essential tremor. Neuromolecular Med 10:356–361CrossRefPubMedGoogle Scholar
  50. Leu-Semenescu S, De Cock VC, Le Masson VD, Debs R, Lavault S, Roze E, Vidailhet M, Arnulf I (2011) Hallucinations in narcolepsy with and without cataplexy: contrasts with Parkinson’s disease. Sleep Med 12:497–504CrossRefPubMedGoogle Scholar
  51. Lieberman P (2009) Histamine, antihistamines, and the central nervous system. Allergy Asthma Proc 30:482–486CrossRefPubMedGoogle Scholar
  52. Lin JS (2000) Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev 4:471–503CrossRefPubMedGoogle Scholar
  53. Lin JS, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, Kocher L, Yanagisawa M, Lehert P, Ligneau X, Perrin D, Robert P, Roux M, Lecomte JM, Schwartz JC (2008) An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin−/− mice and patients. Neurobiol Dis 30:74–83CrossRefPubMedGoogle Scholar
  54. Liu CQ, Chen Z, Liu FX, Hu DN, Luo JH (2007) Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats. Neuropharmacology 53:832–841CrossRefPubMedGoogle Scholar
  55. Liu CQ, Shan L, Balesar R, Luchetti S, Van Heerikhuize JJ, Luo JH, Swaab DF, Bao AM (2010) A quantitative in situ hybridization protocol for formalin-fixed paraffin-embedded archival post-mortem human brain tissue. Methods 52:359–366CrossRefPubMedGoogle Scholar
  56. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA (2000) Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 48:830–843CrossRefPubMedGoogle Scholar
  57. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, Schwalb JM, Kennedy SH (2005) Deep brain stimulation for treatment-resistant depression. Neuron 45:651–660CrossRefPubMedGoogle Scholar
  58. Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, Cilia J, Cluderay JE, Crook B, Davis JB, Davis RK, Davis RP, Dawson LA, Foley AG, Gartlon J, Gonzalez MI, Heslop T, Hirst WD, Jennings C, Jones DN, Lacroix LP, Martyn A, Ociepka S, Ray A, Regan CM, Roberts JC, Schogger J, Southam E, Stean TO, Trail BK, Upton N, Wadsworth G, Wald JA, White T, Witherington J, Woolley ML, Worby A, Wilson DM (2007) GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer’s disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 321:1032–1045CrossRefPubMedGoogle Scholar
  59. Meskanen K, Ekelund H, Laitinen J, Neuvonen PJ, Haukka J, Panula P, Ekelund J (2013) A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia. J Clin Psychopharmacol 33:472–478CrossRefPubMedGoogle Scholar
  60. Mizuguchi H, Yabumoto M, Imamura I, Fukui H, Wada H (1990) Immuno-cross-reactivity of histidine and dopa decarboxylases. Biochem Biophys Res Commun 173:1299–1303CrossRefPubMedGoogle Scholar
  61. Monczor F, Copsel S, Fernandez N, Davio C, Shayo C (2017) Histamine H2-receptor in blood cells: a suitable target for the treatment of acute myeloid leukemia. Handb Exp Pharmacol. doi:  10.1007/164_2016_8
  62. Motawaj M, Peoc’h K, Callebert J, Arrang JM (2010) CSF levels of the histamine metabolite tele-methylhistamine are only slightly decreased in Alzheimer’s disease. J Alzheimers Dis 22:861–871CrossRefPubMedGoogle Scholar
  63. Nakai T, Kitamura N, Hashimoto T, Kajimoto Y, Nishino N, Mita T, Tanaka C (1991) Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia. Biol Psychiatry 30:349–356CrossRefPubMedGoogle Scholar
  64. Nakamura S, Ohnishi K, Nishimura M, Suenaga T, Akiguchi I, Kimura J, Kimura T (1996) Large neurons in the tuberomammillary nucleus in patients with Parkinson’s disease and multiple system atrophy. Neurology 46:1693–1696CrossRefPubMedGoogle Scholar
  65. Neumann D (2017) Role of the histamine H4-receptor in bronchial asthma. Handb Exp Pharmacol. doi:  10.1007/164_2016_11
  66. Orange PR, Heath PR, Wright SR, Ramchand CN, Kolkeiwicz L, Pearson RC (1996) Individuals with schizophrenia have an increased incidence of the H2R649G allele for the histamine H2 receptor gene. Mol Psychiatry 1:466–469PubMedGoogle Scholar
  67. Overeem S, Mignot E, van Dijk JG, Lammers GJ (2001) Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 18:78–105CrossRefPubMedGoogle Scholar
  68. Oyewumi LK, Vollick D, Merskey H, Plumb C (1994) Famotidine as an adjunct treatment of resistant schizophrenia. J Psychiatry Neurosci 19:145–150PubMedCentralPubMedGoogle Scholar
  69. Palada V, Terzic J, Mazzulli J, Bwala G, Hagenah J, Peterlin B, Hung AY, Klein C, Krainc D (2012) Histamine N-methyltransferase Thr105Ile polymorphism is associated with Parkinson’s disease. Neurobiol Aging 33(836):e831–e833Google Scholar
  70. Pang YP, Zheng XE, Weinshilboum RM (2001) Theoretical 3D model of histamine N-methyltransferase: insights into the effects of a genetic polymorphism on enzymatic activity and thermal stability. Biochem Biophys Res Commun 287:204–208CrossRefPubMedGoogle Scholar
  71. Panula P, Nuutinen S (2013) The histaminergic network in the brain: basic organization and role in disease. Nat Rev 14:472–487CrossRefGoogle Scholar
  72. Panula P, Chazot PL, Cowart M, Gutzmer R, Leurs R, Liu WL, Stark H, Thurmond RL, Haas HL (2015) International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. Pharmacol Rev 67:601–655PubMedCentralCrossRefPubMedGoogle Scholar
  73. Passani MB, Blandina P (2011) Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol Sci 32:242–249CrossRefPubMedGoogle Scholar
  74. Perry E, Court J, Goodchild R, Griffiths M, Jaros E, Johnson M, Lloyd S, Piggott M, Spurden D, Ballard C, McKeith I, Perry R (1998) Clinical neurochemistry: developments in dementia research based on brain bank material. J Neural Transm 105:915–933CrossRefPubMedGoogle Scholar
  75. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, Mignot E (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6:991–997CrossRefPubMedGoogle Scholar
  76. Pittenger C (2017) Histamine decarboxylase deficiency as a cause for Tourette syndrome. Handb Exp Pharmacol. doi: 10.1007/164_2016_127Google Scholar
  77. Plazzi G, Fabbri C, Pizza F, Serretti A (2015) Schizophrenia-like symptoms in narcolepsy type 1: shared and distinctive clinical characteristics. Neuropsychobiology 71:218–224CrossRefPubMedGoogle Scholar
  78. Prell GD, Green JP (1991) Histamine metabolites and pros-methylimidazoleacetic acid in human cerebrospinal fluid. Agents Actions Suppl 33:343–363CrossRefPubMedGoogle Scholar
  79. Prell GD, Khandelwal JK, Burns RS, Blandina P, Morrishow AM, Green JP (1991) Levels of pros-methylimidazoleacetic acid: correlation with severity of Parkinson’s disease in CSF of patients and with the depletion of striatal dopamine and its metabolites in MPTP-treated mice. J Neural Transm 3:109–125CrossRefGoogle Scholar
  80. Preuss CV, Wood TC, Szumlanski CL, Raftogianis RB, Otterness DM, Girard B, Scott MC, Weinshilboum RM (1998) Human histamine N-methyltransferase pharmacogenetics: common genetic polymorphisms that alter activity. Mol Pharmacol 53:708–717PubMedGoogle Scholar
  81. Rinne JO, Anichtchik OV, Eriksson KS, Kaslin J, Tuomisto L, Kalimo H, Roytta M, Panula P (2002) Increased brain histamine levels in Parkinson’s disease but not in multiple system atrophy. J Neurochem 81:954–960CrossRefPubMedGoogle Scholar
  82. Rosse RB, Kendrick K, Fay-McCarthy M, Prell GD, Rosenberg P, Tsui LC, Wyatt RJ, Deutsch SI (1996) An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy. Clin Neuropharmacol 19:341–348CrossRefPubMedGoogle Scholar
  83. Roth T, Rogowski R, Hull S, Schwartz H, Koshorek G, Corser B, Seiden D, Lankford A (2007) Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 30:1555–1561PubMedCentralCrossRefPubMedGoogle Scholar
  84. Rutherford K, Parson WW, Daggett V (2008) The histamine N-methyltransferase T105I polymorphism affects active site structure and dynamics. Biochemistry 47:893–901CrossRefPubMedGoogle Scholar
  85. Sanna MD, Ghelardini C, Thurmond RL, Masini E, Galeotti N (2017) Behavioural phenotype of histamine H4 receptor knockout mice: focus on central neuronal functions. Neuropharmacology 114:48–57CrossRefPubMedGoogle Scholar
  86. Schlicker E, Kathmann M (2017) Role of the histamine H3-receptor in the central nervous system. Handb Exp Pharmacol. doi:  10.1007/164_2016_12
  87. Schneider EH, Seifert R (2016) The histamine H-receptor and the central and peripheral nervous system: a critical analysis of the literature. Neuropharmacology 106:116–128CrossRefPubMedGoogle Scholar
  88. Schneider EH, Neumann D, Seifert R (2014a) Modulation of behavior by the histaminergic system: lessons from H(1)R-and H(2)R-deficient mice. Neurosci Biobehav Rev 42:252–266CrossRefPubMedGoogle Scholar
  89. Schneider EH, Neumann D, Seifert R (2014b) Modulation of behavior by the histaminergic system: lessons from HDC-, H3R- and H4R-deficient mice. Neurosci Biobehav Rev 47:101–121CrossRefPubMedGoogle Scholar
  90. Shan L, Bossers K, Luchetti S, Balesar R, Lethbridge N, Chazot PL, Bao AM, Swaab DF (2012a) Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson’s patients: a postmortem study. Neurobiol Aging 33(1488):e1481–e1413Google Scholar
  91. Shan L, Bossers K, Unmehopa U, Bao AM, Swaab DF (2012b) Alterations in the histaminergic system in Alzheimer’s disease: a postmortem study. Neurobiol Aging 33:2585–2598CrossRefPubMedGoogle Scholar
  92. Shan L, Hofman MA, van Wamelen DJ, Van Someren EJ, Bao AM, Swaab Dick F (2012c) Diurnal fluctuation in histidine decarboxylase expression, the rate limiting enzyme for histamine production, and its disorder in neurodegenerative diseases. Sleep 35:713–715PubMedCentralCrossRefPubMedGoogle Scholar
  93. Shan L, Liu CQ, Balesar R, Hofman MA, Bao AM, Swaab DF (2012d) Neuronal histamine production remains unaltered in Parkinson’s disease despite the accumulation of Lewy bodies and Lewy neurites in the tuberomamillary nucleus. Neurobiol Aging 33:1343–1344CrossRefPubMedGoogle Scholar
  94. Shan L, Qi XR, Balesar R, Swaab DF, Bao AM (2013a) Unaltered histaminergic system in depression: a postmortem study. J Affect Disord 146:220–223CrossRefPubMedGoogle Scholar
  95. Shan L, Swaab DF, Bao AM (2013b) Neuronal histaminergic system in aging and age-related neurodegenerative disorders. Exp Gerontol 48:603–607CrossRefPubMedGoogle Scholar
  96. Shan L, Schipper P, Nonkes LJ, Homberg JR (2014) Impaired fear extinction as displayed by serotonin transporter knockout rats housed in open cages is disrupted by IVC cage housing. PLoS One 9:e91472PubMedCentralCrossRefPubMedGoogle Scholar
  97. Shan L, Bao AM, Swaab DF (2015a) The human histaminergic system in neuropsychiatric disorders. Trends Neurosci 38:167–177CrossRefPubMedGoogle Scholar
  98. Shan L, Dauvilliers Y, Siegel JM (2015b) Interactions of the histamine and hypocretin systems in CNS disorders. Nat Rev Neurol 11:401–413CrossRefPubMedGoogle Scholar
  99. Shiroshi M, Kobayashi T (2017) Structural analysis of the histamine H1-receptor. Handb Exp Pharmacol. doi:  10.1007/164_2016_10
  100. Tabuchi S, Tsunematsu T, Black SW, Tominaga M, Maruyama M, Takagi K, Minokoshi Y, Sakurai T, Kilduff TS, Yamanaka A (2014) Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function. J Neurosci 34:6495–6509PubMedCentralCrossRefPubMedGoogle Scholar
  101. Talih FR (2011) Narcolepsy presenting as schizophrenia: a literature review and two case reports. Innov Clin Neurosci 8:30–34PubMedCentralPubMedGoogle Scholar
  102. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM (2000) Reduced number of hypocretin neurons in human narcolepsy. Neuron 27:469–474CrossRefPubMedGoogle Scholar
  103. Tongsook C, Niederhauser J, Kronegger E, Straganz G, Macheroux P (2016) Leucine 208 in human histamine N-methyltransferase emerges as a hotspot for protein stability rationalizing the role of the L208P variant in intellectual disability. Biochim Biophys Acta 1863:188–199CrossRefPubMedGoogle Scholar
  104. Tsuang D, DiGiacomo L, Lipe H, Bird TD (1998) Familial aggregation of schizophrenia-like symptoms in Huntington’s disease. Am J Med Genet 81:323–327CrossRefPubMedGoogle Scholar
  105. Tsuang D, Almqvist EW, Lipe H, Strgar F, DiGiacomo L, Hoff D, Eugenio C, Hayden MR, Bird TD (2000) Familial aggregation of psychotic symptoms in Huntington’s disease. Am J Psychiatry 157:1955–1959CrossRefPubMedGoogle Scholar
  106. Valko PO, Gavrilov YV, Yamamoto M, Reddy H, Haybaeck J, Mignot E, Baumann CR, Scammell TE (2013) Increase of histaminergic tuberomammillary neurons in narcolepsy. Ann Neurol 74:794–804CrossRefPubMedGoogle Scholar
  107. van Wamelen DJ, Shan L, Aziz NA, Anink JJ, Bao AM, Roos RA, Swaab DF (2011) Functional increase of brain histaminergic signaling in Huntington’s disease. Brain Pathol 21:419–427CrossRefPubMedGoogle Scholar
  108. Vizuete ML, Merino M, Venero JL, Santiago M, Cano J, Machado A (2000) Histamine infusion induces a selective dopaminergic neuronal death along with an inflammatory reaction in rat substantia nigra. J Neurochem 75:540–552CrossRefPubMedGoogle Scholar
  109. Yanai K, Tashiro M (2007) The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies. Pharmacol Ther 113:1–15CrossRefPubMedGoogle Scholar
  110. Yang X, Liu C, Zhang J, Han H, Wang X, Liu Z, Xu Y (2015) Association of histamine N-methyltransferase Thr105Ile polymorphism with Parkinson’s disease and schizophrenia in Han Chinese: a case-control study. PLoS One 10:e0119692PubMedCentralCrossRefPubMedGoogle Scholar
  111. Yu X, Zecharia A, Zhang Z, Yang Q, Yustos R, Jager P, Vyssotski AL, Maywood ES, Chesham JE, Ma Y, Brickley SG, Hastings MH, Franks NP, Wisden W (2014) Circadian factor BMAL1 in histaminergic neurons regulates sleep architecture. Curr Biol 24:2838–2844PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of Neurobiology, Key Laboratory of Medical Neurobiology of Ministry of Health of China, Zhejiang Province Key Laboratory of NeurobiologyZhejiang University School of MedicineHangzhouChina
  2. 2.Netherlands Institute for Neuroscience, Institute of the Royal Netherlands Academy of Arts and SciencesUniversity of AmsterdamAmsterdamThe Netherlands

Personalised recommendations